Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more
Teva Pharmaceutical Industries Limited (TEVJF) - Total Liabilities
Latest total liabilities as of December 2025: $32.84 Billion USD
Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEVJF) has total liabilities worth $32.84 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Teva Pharmaceutical Industries Limited - Total Liabilities Trend (1985–2025)
This chart illustrates how Teva Pharmaceutical Industries Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Teva Pharmaceutical Industries Limited Competitors by Total Liabilities
The table below lists competitors of Teva Pharmaceutical Industries Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trimble Inc
NASDAQ:TRMB
|
USA | $3.48 Billion |
|
H4W0
F:H4W0
|
Germany | €31.74 Billion |
|
Emera Incorporated
NYSE:EMA
|
USA | $31.40 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $22.70 Billion |
|
Corem Property Group AB (publ)
ST:CORE-D
|
Sweden | Skr36.64 Billion |
|
FinecoBank Banca Fineco S.p.A
PINK:FNBKY
|
USA | $33.11 Billion |
|
Magna International Inc
NYSE:MGA
|
USA | $19.95 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Teva Pharmaceutical Industries Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Teva Pharmaceutical Industries Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Teva Pharmaceutical Industries Limited (1985–2025)
The table below shows the annual total liabilities of Teva Pharmaceutical Industries Limited from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $32.84 Billion | -2.28% |
| 2024-12-31 | $33.61 Billion | -4.94% |
| 2023-12-31 | $35.35 Billion | +0.11% |
| 2022-12-31 | $35.31 Billion | -3.04% |
| 2021-12-31 | $36.42 Billion | -7.98% |
| 2020-12-31 | $39.58 Billion | -6.67% |
| 2019-12-31 | $42.41 Billion | -5.53% |
| 2018-12-31 | $44.89 Billion | -13.46% |
| 2017-12-31 | $51.87 Billion | -10.41% |
| 2016-12-31 | $57.90 Billion | +137.96% |
| 2015-12-31 | $24.33 Billion | +5.49% |
| 2014-12-31 | $23.07 Billion | -7.27% |
| 2013-12-31 | $24.87 Billion | -10.35% |
| 2012-12-31 | $27.74 Billion | -0.21% |
| 2011-12-31 | $27.80 Billion | +63.04% |
| 2010-12-31 | $17.05 Billion | +17.17% |
| 2009-12-31 | $14.55 Billion | -12.05% |
| 2008-12-31 | $16.54 Billion | +71.40% |
| 2007-12-31 | $9.65 Billion | +3.85% |
| 2006-12-31 | $9.29 Billion | +114.29% |
| 2005-12-31 | $4.34 Billion | +2.48% |
| 2004-12-31 | $4.23 Billion | +61.55% |
| 2003-12-31 | $2.62 Billion | -6.18% |
| 2002-12-31 | $2.79 Billion | +34.43% |
| 2001-12-31 | $2.08 Billion | +22.01% |
| 2000-12-31 | $1.70 Billion | +75.22% |
| 1999-12-31 | $971.72 Million | +25.16% |
| 1998-12-31 | $776.40 Million | +34.89% |
| 1997-12-31 | $575.60 Million | -18.49% |
| 1996-12-31 | $706.20 Million | +52.30% |
| 1995-12-31 | $463.70 Million | +39.00% |
| 1994-12-31 | $333.60 Million | +13.08% |
| 1993-12-31 | $295.00 Million | +32.94% |
| 1992-12-31 | $221.90 Million | +14.56% |
| 1991-12-31 | $193.70 Million | -6.96% |
| 1990-12-31 | $208.20 Million | +24.45% |
| 1989-12-31 | $167.30 Million | +12.28% |
| 1988-12-31 | $149.00 Million | +75.29% |
| 1986-12-31 | $85.00 Million | -4.71% |
| 1985-12-31 | $89.20 Million | -- |